Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ibutilide: a new class III antiarrhythmic agent

M C Granberry1

  • 1Department of Pharmacy Practice, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|March 10, 1998
PubMed
Summary

Ibutilide effectively restores normal sinus rhythm in patients with recent-onset atrial fibrillation or flutter. This Class III antiarrhythmic agent demonstrates significant efficacy, though ventricular tachycardia is a primary concern.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anticoagulation management in mechanical heart valve patients who undergo dental procedures.

The Journal of the Arkansas Medical Society·2003
Same author

Lovastatin inhibits phenylephrine-induced ERK activation and growth of cardiac.

Cardiovascular toxicology·2002
Same author

Raising HDL-C to prevent atherosclerotic events.

The Journal of the Arkansas Medical Society·2000
Same author

Insulin resistance syndrome: options for treatment.

Southern medical journal·1999
Same author

The role of troglitazone in treating the insulin resistance syndrome.

Pharmacotherapy·1998
Same author

Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control.

The Annals of pharmacotherapy·1997

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiology

Background:

  • Ibutilide is a Class III antiarrhythmic agent.
  • It functions by activating a slow inward sodium current, prolonging action potential and effective refractory period in atrial and ventricular tissues.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and administration of ibutilide.
  • To assess ibutilide's role in treating atrial fibrillation and atrial flutter.

Main Methods:

  • Review of existing pharmacological and clinical trial data.
  • Analysis of pharmacokinetic properties including metabolism and elimination half-life.
  • Evaluation of clinical efficacy in converting arrhythmias and assessment of adverse events.

Main Results:

Related Experiment Videos

  • Ibutilide is indicated for rapid restoration of normal sinus rhythm in hemodynamically stable patients with recent-onset atrial fibrillation or flutter.
  • Efficacy in converting atrial flutter is higher than atrial fibrillation, but conversion is faster for atrial fibrillation.
  • Ventricular tachycardia occurred in 4.3% of patients; efficacy was superior to sotalol in one study.

Conclusions:

  • Ibutilide is an effective alternative antiarrhythmic agent for rapid conversion of arrhythmias.
  • Dosage is concentration-dependent, with recommendations based on weight and a potential need for a second dose.
  • The drug undergoes extensive hepatic metabolism with a six-hour elimination half-life.